How can the spatial interactions of the tumour immune microenvironment reveal prognostic insights into Follicular Lymphoma? We ask Martin Fergie, Lecturer in Healthcare Sciences at the University of Manchester.

Amanda Heslegrave, Senior Research Fellow at the UK Dementia Research Centre, UCL, showcases cutting-edge super sensitive immunoassay research at Biomarkers UK 2021.

The Genomics Organisation for Academic Laboratories – known also to the world as GOAL – is a collaborative project set up by a group of academic centres across the United States to facilitate affordable next generation sequencing. The long-term target is to expand patient access to personalised genomic testing, as well as future biomarker discovery.

Erin Newburn, Senior Director, Field Applications Scientist at Personalis, Inc. showcases the Personalis NeXT Platform ®, a tumour profiling solution for both tissue and liquid biopsies at Biomarkers UK 2022.

Anna Lyubetskaya, Senior Principal Scientist at Bristol Myers Squibb, leads a discussion on the industry landscape and ‘Current Status of Omics-Based Biomarkers.’

Quantitative mass spectrometry offers a clinical tool for the discovery of biomarkers, which can be vital in helping to treat certain cancers. In this Commentary article, we explore the applications of mass spectrometry for the identification of triple negative breast cancer and some of the implications for future research.

Senior representatives from Ultivue, Genentech, and GSK discuss the current trends and opportunities in enabling the future of multi-omics-based analysis.

Yu Liang, Director of Clinical Biomarkers at Compugen, leads a discussion on ‘Spatial Biomarkers & Multiplexed Immunofluorescence in Immuno-Oncology.’

From maximising immune response with combination biomarkers to conducting diagnostic innovation in immunotherapy prognosis, the future of predictive biomarkers is fast approaching. We speak to senior representatives from industry and academia to find out more.

Three key take aways when you develop biomarkers: one during biomarker discovery, one during biomarker development and one during biomarker validation.

Discovering a strong biomarker is an expensive and time-consuming process. One of the key takeaways is to take your time and look at the data before you start testing for biomarkers.

Biomarkers come in many shapes and sizes. It’s an ever-evolving subject with many under-discovered possibilities. Let’s look at some ways biomarkers are looking to evolve.